2021

EpicentRx Publishes Proof-of-Concept Research on AdAPT-001

EpicentRx Publishes Proof-of-Concept Research on AdAPT-001

Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap LA JOLLA, Calif., December 8, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...

read more
EpicentRx, Inc. in an Expansive Growth Phase

EpicentRx, Inc. in an Expansive Growth Phase

Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...

read more